208 related articles for article (PubMed ID: 26172269)
1. BCL2 Inhibitor (ABT-737): A Restorer of Prednisolone Sensitivity in Early T-Cell Precursor-Acute Lymphoblastic Leukemia with High MEF2C Expression?
Kawashima-Goto S; Imamura T; Tomoyasu C; Yano M; Yoshida H; Fujiki A; Tamura S; Osone S; Ishida H; Morimoto A; Kuroda H; Hosoi H
PLoS One; 2015; 10(7):e0132926. PubMed ID: 26172269
[TBL] [Abstract][Full Text] [Related]
2. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.
Kohl TM; Hellinger C; Ahmed F; Buske C; Hiddemann W; Bohlander SK; Spiekermann K
Leukemia; 2007 Aug; 21(8):1763-72. PubMed ID: 17554384
[TBL] [Abstract][Full Text] [Related]
3. Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy.
Karlsson H; Lindqvist AC; Fransson M; Paul-Wetterberg G; Nilsson B; Essand M; Nilsson K; Frisk P; Jernberg-Wiklund H; Loskog A
Cancer Gene Ther; 2013 Jul; 20(7):386-93. PubMed ID: 23788110
[TBL] [Abstract][Full Text] [Related]
4. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.
Peirs S; Matthijssens F; Goossens S; Van de Walle I; Ruggero K; de Bock CE; Degryse S; Canté-Barrett K; Briot D; Clappier E; Lammens T; De Moerloose B; Benoit Y; Poppe B; Meijerink JP; Cools J; Soulier J; Rabbitts TH; Taghon T; Speleman F; Van Vlierberghe P
Blood; 2014 Dec; 124(25):3738-47. PubMed ID: 25301704
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP
J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement.
Jayanthan A; Incoronato A; Singh A; Blackmore C; Bernoux D; Lewis V; Stam R; Whitlock JA; Narendran A
Pediatr Blood Cancer; 2011 Mar; 56(3):353-60. PubMed ID: 21225911
[TBL] [Abstract][Full Text] [Related]
7. Combination of ABT-737 and resveratrol enhances DNA damage and apoptosis in human T-cell acute lymphoblastic leukemia MOLT-4 cells.
Opydo-Chanek M; Rak A; Cierniak A; Mazur L
Toxicol In Vitro; 2017 Aug; 42():38-46. PubMed ID: 28366708
[TBL] [Abstract][Full Text] [Related]
8. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.
High LM; Szymanska B; Wilczynska-Kalak U; Barber N; O'Brien R; Khaw SL; Vikstrom IB; Roberts AW; Lock RB
Mol Pharmacol; 2010 Mar; 77(3):483-94. PubMed ID: 20038611
[TBL] [Abstract][Full Text] [Related]
9. Induction of apoptosis in pediatric acute lymphoblastic leukemia (ALL) cells by the therapeutic opioid methadone and effective synergy with Bcl-2 inhibition.
Singh A; Jayanthan A; Farran A; Elwi AN; Kim SW; Farran P; Narendran A
Leuk Res; 2011 Dec; 35(12):1649-57. PubMed ID: 21798596
[TBL] [Abstract][Full Text] [Related]
10. Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma.
Kunami N; Katsuya H; Nogami R; Ishitsuka K; Tamura K
Anticancer Res; 2014 Oct; 34(10):5287-94. PubMed ID: 25275021
[TBL] [Abstract][Full Text] [Related]
11. Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737.
Ishitsuka K; Kunami N; Katsuya H; Nogami R; Ishikawa C; Yotsumoto F; Tanji H; Mori N; Takeshita M; Miyamoto S; Tamura K
Cancer Lett; 2012 Apr; 317(2):218-25. PubMed ID: 22138435
[TBL] [Abstract][Full Text] [Related]
12. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
Kuroda J; Kimura S; Andreeff M; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Murotani Y; Matsumoto Y; Tanaka H; Strasser A; Taniwaki M; Maekawa T
Br J Haematol; 2008 Jan; 140(2):181-90. PubMed ID: 18028486
[TBL] [Abstract][Full Text] [Related]
13. Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia.
Wu X; Wang L; Qiu Y; Zhang B; Hu Z; Jin R
Int J Nanomedicine; 2017; 12():8025-8034. PubMed ID: 29184402
[TBL] [Abstract][Full Text] [Related]
14. Ceramide synthase-6 confers resistance to chemotherapy by binding to CD95/Fas in T-cell acute lymphoblastic leukemia.
Verlekar D; Wei SJ; Cho H; Yang S; Kang MH
Cell Death Dis; 2018 Sep; 9(9):925. PubMed ID: 30206207
[TBL] [Abstract][Full Text] [Related]
15. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins.
Tagscherer KE; Fassl A; Campos B; Farhadi M; Kraemer A; Böck BC; Macher-Goeppinger S; Radlwimmer B; Wiestler OD; Herold-Mende C; Roth W
Oncogene; 2008 Nov; 27(52):6646-56. PubMed ID: 18663354
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
Kuroda J; Kimura S; Strasser A; Andreeff M; O'Reilly LA; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Tabe Y; Taniwaki M; Maekawa T
Cell Death Differ; 2007 Sep; 14(9):1667-77. PubMed ID: 17510658
[TBL] [Abstract][Full Text] [Related]
18. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
19. The Bcl-2/Bcl-XL inhibitor ABT-737 promotes death of retinoblastoma cancer cells.
Allaman-Pillet N; Oberson A; Munier F; Schorderet DF
Ophthalmic Genet; 2013; 34(1-2):1-13. PubMed ID: 21955141
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S
Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
